A Nationwide Descriptive Analysis of Real‐World Outcomes After Radical Prostatectomy in Japan Using the National Clinical Database
Authors:
- Shinichi SakamotoShinichi Sakamoto
- Kyoko YamamotoKYKyoko Yamamoto
- Hiroyuki YamamotoHYHiroyuki Yamamoto
- Shingo HatakeyamaSHShingo Hatakeyama
- Ryuichi MizunoRMRyuichi Mizuno
- Takahiro YasuiTakahiro Yasui
- Toshiyuki KamotoTKToshiyuki Kamoto
- Eiji KikuchiEKEiji Kikuchi
- Akihiro ItoAIAkihiro Ito
- Haruki KumeHKHaruki Kume
- 17 July 2026
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 33 (7) , e70567
Abstract
Objectives: To evaluate real‐world biochemical recurrence‐free survival (BCRFS) after radical prostatectomy (RP) for prostate cancer in Japan using nationwide data from the National Clinical Database (NCD). Methods: This study included patients who underwent RP between April and December 2018 and were registered in the NCD from 647 participating institutions. BCRFS was estimated using the Kaplan–Meier method. Outcomes were evaluated according to surgical approach and clinicopathological factors without adjustment for baseline characteristics. Results: A total of 14 992 patients with available 5‐year postoperative follow‐up data were included in the analysis. Robot‐assisted RP accounted for the majority of procedures (73.2%), followed by open RP (16.0%) and laparoscopic RP (10.8%). The overall 5‐year BCRFS rate was 81%. BCRFS was comparable across age groups and surgical approaches. In contrast, pathological factors strongly influenced prognosis. Five‐year BCRFS decreased with increasing pathological stage (pT2, 86%; pT3, 65%; pT4, 41%) and was lower in patients with nodal metastasis (pN0, 81%; pN1, 59%). The International Society of Urological Pathology (ISUP) Grade Group demonstrated a stepwise association with prognosis, with 5‐year BCRFS declining from 92% in grade group 1 to 60% in grade group 5. Five‐year BCRFS was lowest in the extended lymph node dissection group (73%), followed by the obturator lymph node dissection group (80%) and the no‐dissection group (87%). Conclusions: Current nationwide data delineate the real‐world oncological outcomes following RP in Japan. Pathological tumor characteristics—rather than patient age or surgical approach—were the predominant determinants of postoperative prognosis. These findings may provide essential benchmarks to guide clinical decision‐making.Keywords
This publication has 15 references indexed in Scilit:
- Safety of Robot‐Assisted Radical Cystectomy for Muscle‐Invasive Bladder Cancer: A Real‐World Analysis Using the National Clinical Database in JapanCancer Medicine, 2025
- Risk of Biochemical Recurrence and Metastasis in Prostate Cancer Patients Treated with Radical Prostatectomy After a 10-year Disease-free IntervalEuropean Urology Oncology, 2024
- Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerNew England Journal of Medicine, 2023
- Disparities in access to robotic technology and perioperative outcomes among patients treated with radical prostatectomyJournal of Surgical Oncology, 2023
- Comparison of Acute and Chronic Surgical Complications Following Robot-Assisted, Laparoscopic, and Traditional Open Radical Prostatectomy Among Men in TaiwanJAMA Network Open, 2021
- Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 TrialEuropean Urology, 2021
- Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancerCochrane Database of Systematic Reviews, 2017
- Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based CohortEuropean Urology, 2016
- Validation of a contemporary prostate cancer grading system using prostate cancer death as outcomeBritish Journal of Cancer, 2016
- Pathologic findings at radical prostatectomy: Risk factors for failure and deathUrologic Oncology: Seminars and Original Investigations, 2007